Gallium-68 satoreotide

Drug Profile

Gallium-68 satoreotide

Alternative Names: 68Ga-DOTA-JR11; 68Ga-OPS202; 68Ga-satoreotide; OPS 202; SOMscan

Latest Information Update: 20 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OctreoPharm Sciences
  • Developer Ipsen; Memorial Sloan-Kettering Cancer Center; OctreoPharm Sciences
  • Class Imaging agents; Peptides; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neuroendocrine tumours

Most Recent Events

  • 09 Jul 2017 Phase-II clinical trials in Neuroendocrine tumours (Diagnosis) in Austria (Parenteral) (EudraCT2016-004928-39)
  • 02 Jun 2017 Preliminary efficacy and adverse events data from a phase I trial in Neuroendocrine tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 06 Sep 2016 Phase-II clinical trials in Neuroendocrine tumours (Diagnosis) in Switzerland (Parenteral) before September 2016 (Ipsen pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top